SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others. Further expanding its therapeutic offerings, SanBio is developing SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 as a treatment for cancer, and MSC2 targeting inflammatory diseases and optic neuritis. The company was established in 2001 and is headquartered in Tokyo, Japan.
—
SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others. Further expanding its therapeutic offerings, SanBio is developing SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 as a treatment for cancer, and MSC2 targeting inflammatory diseases and optic neuritis. The company was established in 2001 and is headquartered in Tokyo, Japan.
—
Daily adjusted close
SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others. Further expanding its therapeutic offerings, SanBio is developing SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 as a treatment for cancer, and MSC2 targeting inflammatory diseases and optic neuritis. The company was established in 2001 and is headquartered in Tokyo, Japan.